Skip to content
type1.science
Phase 3RecruitingNCT06894784

SEMPA: semaglutide plus empagliflozin added to AID

What this study tests

McGill phase 3 crossover study testing semaglutide and empagliflozin, individually and combined, as adjuncts to automated insulin delivery in adults with T1D.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2025-03-30.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Adults with T1D for at least one year, AID use for at least three months and BMI at least 23 kg/m². Recent severe hypoglycemia or DKA, pregnancy, and several gastrointestinal, retinal and renal conditions are exclusions; see registry for the complete criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted yet.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: Canada. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • Time in range

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]